| Literature DB >> 36115914 |
Yong Qin1, Jinhua Cai2, Lu Tian3, Xiaomeng Li4, Helin Zheng4, Longlun Wang4.
Abstract
Computed tomography (CT) has been widely used for the diagnosis of pelvic rhabdomyosarcoma (RMS) in children. However, it is difficult to differentiate pelvic RMS from other pelvic malignancies. This study aimed to analyze and select CT features by using least absolute shrinkage and selection operator (LASSO) logistic regression and established a Fisher discriminant analysis (FDA) model for the quantitative diagnosis of pediatric pelvic RMS. A total of 121 pediatric patients who were diagnosed with pelvic neoplasms were included in this study. The patients were assigned to an RMS group (n = 36) and a non-RMS group (n = 85) according to the pathological results. LASSO logistic regression was used to select characteristic features, and an FDA model was constructed for quantitative diagnosis. Leave-one-out cross-validation and receiver operating characteristic (ROC) curve analysis were used to evaluate the diagnostic ability of the FDA model. Six characteristic variables were selected by LASSO logistic regression, all of which were CT morphological features. Using these CT features, the following diagnostic models were established: (RMS group)[Formula: see text]; (Non-RMS group)[Formula: see text], where [Formula: see text], [Formula: see text], … and [Formula: see text] are lower than normal muscle density (1 = yes; 0 = no), multinodular fusion (1 = yes; 0 = no), enhancement at surrounding blood vessels (1 = yes; 0 = no), heterogeneous progressive centripetal enhancement (1 = yes; 0 = no), ring enhancement (1 = yes; 0 = no), and hemorrhage (1 = yes; 0 = no), respectively. The calculated area under the ROC curve (AUC) of the model was 0.992 (0.982-1.000), with a sensitivity of 94.4%, a specificity of 96.5%, and an accuracy of 95.9%. The calculated sensitivity, specificity and accuracy values were consistent with those from cross-validation. An FDA model based on the CT morphological features of pelvic RMS was established and could provide an easy and efficient method for the diagnosis and differential diagnosis of pelvic RMS in children.Entities:
Mesh:
Year: 2022 PMID: 36115914 PMCID: PMC9482627 DOI: 10.1038/s41598-022-20051-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Comparison of the basic and CT morphological characteristics between the RMS group and the non-RMS group.
| RMS group (n = 36) | Non-RMS group (n = 85) | Statistic | P value | |
|---|---|---|---|---|
| Age (year) Q (Q1–Q3) | 2.5 (1–6.5) | 6 (1–9) | 1.767 a | 0.077 |
| Sex (male/female) | 14/22 | 24/61 | 1.332 b | 0.248 |
| Lower than normal muscle density | 35 (97.2) | 51 (60.4) | 17.043 b | < 0.001 |
| Calcification | 1 (2.8) | 23 (27.1) | 9.377 b | 0.002 |
| Hemorrhage | 5 (13.9) | 28 (32.9) | 4.628 b | 0.031 |
| Necrosis | 35 (97.2) | 71 (83.5) | 0.066 | |
| Multinodular fusion | 23 (63.9) | 10 (11.8) | 34.641 b | < 0.001 |
| Lobulated | 28 (77.8) | 44 (51.8) | 7.102 b | 0.008 |
| Round/orbicular | 6 (16.7) | 22 (25.9) | 1.208 b | 0.272 |
| Unclear | 8 (22.2) | 26 (30.6) | 0.876 b | 0.349 |
| Surrounding blood vessels | 29 (80.6) | 16 (18.8) | 41.257 b | < 0.001 |
| Heterogeneous progressive centripetal enhancement | 31 (86.1) | 10 (11.8) | 62.395 b | < 0.001 |
| Ring enhancement | 5 (13.9) | 6 (7.1) | c | 0.300 |
| Grape cluster reinforcement | 0 (0.0) | 71 (0.0) | – | – |
| Lymphatic metastasis | 12 (33.3) | 14 (16.5) | 4.263 b | 0.039 |
| Bone erosion | 2 (5.6) | 5 (5.9) | c | 1.000 |
Q is the median age, Q1–Q3 are 25–75% quantiles.
CT computed tomography, RMS rhabdomyosarcoma.
aUsing the M–U test.
bUsing the Chi-square test.
cUsing Fisher's exact probability test.
Figure 1LASSO logistic regression plot. (A) Plot of partial likelihood deviance; (B) plot of LASSO coefficient profiles. Each colored curve represents the LASSO coefficient profile of a feature against the log (λ) sequence.
Figure 2Receiver operating characteristic (ROC) curve of the quantitative diagnostic model for pelvic RMS in children using Fisher discriminant analysis.
Results of the Fisher model and cross-validation.
| Predicted (n, %) | ||
|---|---|---|
| RMS | Non-RMS | |
| RMS group | 33 (91.7) | 3 (8.3) |
| Non-RMS group | 2 (2.4) | 83 (97.6) |
| RMS group | 33 (91.7) | 3 (8.3) |
| Non-RMS group | 2 (2.4) | 83 (97.6) |
Figure 3Importance of fisher discriminant model features.
Sensitivity, specificity, AUC and 95% CI of the single characteristic features.
| Se (95% CI) | Sp (95% CI) | AUC (95% CI) | |
|---|---|---|---|
| Heterogeneous progressive centripetal enhancement | 0.861 (0.697–0.948) | 0.882 (0.790–0.939) | 0.872 (0.795–0.948 |
| Enhancement at surrounding blood vessels | 0.806 (0.634–0.912) | 0.812 (0.709–0.885) | 0.809 (0.720–0.898) |
| Multinodular fusion | 0.639 (0.462–0.787) | 0.882 (0.790–0.939) | 0.761 (0.658–0.864) |
| Lower than normal muscle density | 0.972 (0.838–0.999) | 0.400 (0.297–0.512) | 0.686 (0.592–0.780) |
| Hemorrhage | 0.861 (0.697–0.948) | 0.329 (0.234–0.441) | 0.595 (0.489–0.701) |
| Ring enhancement | 0.139 (0.052–0.303) | 0.929 (0.847–0.971) | 0.534 (0.419–0.649) |
Se sensitivity, Sp specificity, CI confidence interval, AUC area under the curve.
Figure 4AUC of fisher's discriminant model and its 95% CI accumulated according to the importance of the features. CI confidence interval, AUC area under the curve.